Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
absence, barrel, benchmark, bolivar, cancellation, Cardinal, Catalent, ceremony, certainty, condensed, consummated, corruption, devaluation, EBITDA, encouraged, entirety, Flynn, Herman, hosted, infrastructure, isolation, Karen, led, lender, MixJectTM, monetary, nondeductibility, NovaGuardTM, official, par, pari, passu, plunger, purity, quantitative, rank, reinstated, Relief, renew, respond, risTM, scale, SelfDoseTM, serum, Taxpayer, unamortized, Venezuelan
Removed:
absent, accelerated, allocate, amendment, arose, Beneficial, Brazil, button, certificate, combination, composed, consolidate, constant, conveniently, deemed, dental, dispensing, divestiture, dosage, Dropper, ear, efficiently, element, eye, fee, fit, fix, flashback, foresee, Gordon, heavily, ideal, identified, infusion, JPY, larger, Lionville, McMillan, met, Mixject, nasal, navigate, Nektar, notice, NovaGuard, November, Pack, passive, pen, Plastef, positive, profile, quicker, ready, realignment, receipt, recurring, reflecting, removable, removed, repaying, repayment, repurchasing, SA, seal, Serbia, sleeve, slightly, small, solution, strength, task, tip, underwriting, VeriSure
Filing tables
Filing exhibits
Related press release
WST similar filings
Filing view
External links
Exhibit 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Forms S-3 (Registration Nos. 333-88358, 333-128438, 333-133863, 333-141130 and 333-145186) and Forms S-8 (Registration Nos. 333-106977, 333-115175, 333-143129, 333-143437, 333-156492 and 333-174153) of West Pharmaceutical Services, Inc. of our report dated February 26, 2013 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
February 27, 2013